We are live on ! Find out more
VTVT icon

vTv Therapeutics
VTVT

44 hedge funds and large institutions have $22.1M invested in vTv Therapeutics in 2017 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 12 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 2

19% more funds holding

Funds holding: 37 → 44 (+7)

8% more capital invested

Capital invested by funds: $20.4M → $22.1M (+$1.66M)

8% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 12

0.07% more ownership

Funds ownership: 0.88% → 0.95% (+0.07%)

Holders
44
Holders Change
+7
Holders Change %
+18.92%
% of All Funds
1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
13
Reduced
12
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RA
Royce & Associates
New York
+$1.26M
2
JP Morgan Chase
JP Morgan Chase
New York
+$715K
3
Millennium Management
Millennium Management
New York
+$351K
4
Creative Planning
Creative Planning
Kansas
+$106K
5
State Street
State Street
Massachusetts
+$70.2K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$391K
2
CS
Candriam SCA
Luxembourg
-$280K
3
Franklin Resources
Franklin Resources
California
-$275K
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$107K
5
SFM
Sphera Funds Management
Israel
-$103K
Name Holding Trade Value Shares
Change 		Change in
Stake
PAM
26
Panagora Asset Management
Massachusetts
$31K +$28.7K +128 New
AIG
27
American International Group
New York
$29K – – –
New York State Common Retirement Fund
28
New York State Common Retirement Fund
New York
$26K – – –
Manulife (Manufacturers Life Insurance)
29
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$16K +$4.04K +18 +37%
Barclays
30
Barclays
United Kingdom
$13K +$8.97K +40 +333%
BNP Paribas Financial Markets
31
BNP Paribas Financial Markets
France
$10.4K +$4.71K +21 +95%
Wells Fargo
32
Wells Fargo
California
$9K +$1.34K +6 +19%
TRCT
33
Tower Research Capital (TRC)
New York
$8K +$7.17K +32 New
Parallax Volatility Advisers
34
Parallax Volatility Advisers
California
$7K +$6.28K +28 New
AG
35
Advisor Group
Arizona
$5K – – –
Legal & General Group
36
Legal & General Group
United Kingdom
$5K – – –
Bank of America
37
Bank of America
North Carolina
$5K +$2.92K +13 +163%
UBS Group
38
UBS Group
Switzerland
$4K +$2.69K +12 +200%
Citigroup
39
Citigroup
New York
$4K +$4.04K +18 New
AIP
40
Ameritas Investment Partners
Nebraska
$3K – – –
NFA
41
Nationwide Fund Advisors
Ohio
– -$29K -122 Closed
FAM
42
Fred Alger Management
New York
– -$6K -25 Closed
Royal Bank of Canada
43
Royal Bank of Canada
Ontario, Canada
– -$2.92K -13 -87%
SWP
44
Stratos Wealth Partners
Ohio
– +$224 +1 New
1
2

VTVT Hedge Fund Activity: Q4 2017 in Review

44 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q4 2017, worth a combined $22.1M — up 8.1% from $20.4M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new VTVT positions and 2 closed out — a net gain of 7 holders — while 13 added to existing stakes and 12 trimmed.

The largest buyer was Royce & Associates, opening a new position worth an estimated $1.26M. The largest seller was BlackRock, cutting an estimated $391K.

  • 44 institutional investors held vTv Therapeutics (VTVT) as of Q4 2017, up from 37 in Q3 2017.
  • Funds reported $22.1M of vTv Therapeutics stock for Q4 2017, up 8.1% quarter-over-quarter.
  • 9 funds opened new vTv Therapeutics positions in Q4 2017 and 2 closed out, a net change of +7 holders.
  • The largest vTv Therapeutics buyer in Q4 2017 was Royce & Associates, an estimated $1.26M added.
  • The largest vTv Therapeutics seller in Q4 2017 was BlackRock, an estimated $391K sold.

Based on aggregated 13F filings for Q4 2017.